{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:30:38Z","timestamp":1792899038273,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective and tolerable treatment for patients with platinum-resistant recurrent ovarian cancer remains a great challenge in clinical practice. This study aimed to evaluate the efficacy and safety of envafolimab, the first subcutaneously administered programmed death ligand 1 (PD-L1) inhibitor, combined with lenvatinib and etoposide in patients with platinum-resistant recurrent ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an open-label, single-arm, phase 2 trial (ENLEN-OC-001). Patients with platinum-resistant recurrent ovarian cancer were eligible for inclusion who were administered envafolimab subcutaneously on day 1 and lenvatinib and etoposide orally on days 1-14, with 21\u2009days as a cycle. After 6-10 cycles, envafolimab and lenvatinib were taken as maintenance therapy until intolerable toxicity, disease progression, withdrawal of consent, or finishing 24\u2009months of treatment. The primary endpoint was objective response rate (ORR), and the secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the screened 28 patients, 21 were included, with 18 being assessed for the efficacy and safety. The ORR was 44.4% (95% CI 21.5%-69.2%), and the DCR was 83.3% (95% CI 58.6%-96.4%). The median PFS was 10.2\u2009months (95% CI 5.6-not applicable [NA]), and the median OS was 21.3\u2009months (95% CI 6.8-NA). The most common grade 3\/4 adverse events were leukopenia (27.8%) and thrombocytopenia (16.7%). No serious adverse events or treatment-related deaths were reported. No changes were observed in the depression, anxiety, and quality of life following treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Envafolimab combined with lenvatinib and etoposide showed promising efficacy and tolerable safety for patients with platinum-resistant recurrent ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                    <jats:p>NCT05422183<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf210","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:10:35Z","timestamp":1752502235000},"source":"Crossref","is-referenced-by-count":2,"title":["Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide"],"prefix":"10.1093","volume":"30","author":[{"given":"Bo","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]},{"name":"Nanjing Key Laboratory of Intelligent Obstetrics and Gynecology Medicine, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiya","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]},{"name":"Nanjing Key Laboratory of Intelligent Obstetrics and Gynecology Medicine, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ji","sequence":"additional","affiliation":[{"name":"Nanjing Key Laboratory of Intelligent Obstetrics and Gynecology Medicine, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]},{"name":"Department of Clinical Science and Research, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lin","sequence":"additional","affiliation":[{"name":"Nanjing Key Laboratory of Intelligent Obstetrics and Gynecology Medicine, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]},{"name":"Department of Clinical Science and Research, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd , Nanjing 210042,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhu","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of General Practice, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-5062","authenticated-orcid":false,"given":"Yang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]},{"name":"Nanjing Key Laboratory of Intelligent Obstetrics and Gynecology Medicine, Zhongda Hospital, School of Medicine, Southeast University , Nanjing 210009,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2025091815422397600_oyaf210-B1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"2025091815422397600_oyaf210-B2","doi-asserted-by":"crossref","first-page":"vi89","DOI":"10.1093\/annonc\/mdz339.028","article-title":"Avelumab in platinum-resistant\/refractory ovarian cancer (PRROC): phase 3 results from JAVELIN ovarian 200","volume":"30","author":"Yonemori","year":"2019","journal-title":"Ann Oncol"},{"key":"2025091815422397600_oyaf210-B3","doi-asserted-by":"crossref","first-page":"S611","DOI":"10.1016\/j.annonc.2020.08.946","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: open-\u00adlabel, randomized trial in Japan (NINJA trial)","volume":"31","author":"Omatsu","year":"2020","journal-title":"Ann Oncol."},{"key":"2025091815422397600_oyaf210-B4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/biomedicines13010168","article-title":"Immunotherapy in recurrent ovarian cancer","volume":"13","author":"Chen","year":"2025","journal-title":"Biomedicines"},{"key":"2025091815422397600_oyaf210-B5","doi-asserted-by":"crossref","first-page":"e003831","DOI":"10.1136\/jitc-2021-003831","article-title":"Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025091815422397600_oyaf210-B6","doi-asserted-by":"crossref","first-page":"100689","DOI":"10.1016\/j.xcrm.2022.100689","article-title":"Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: a multi-center, single-arm, phase 1b trial","volume":"3","author":"Lan","year":"2022","journal-title":"Cell Rep Med"},{"key":"2025091815422397600_oyaf210-B7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/14712598.2022.2125799","article-title":"Envafolimab\u2014first PD-1\/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2025091815422397600_oyaf210-B8","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","article-title":"Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study","volume":"19","author":"Lan","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025091815422397600_oyaf210-B9","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"1 Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025091815422397600_oyaf210-B10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1470-2045(24)00437-6","article-title":"Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Peng","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025091815422397600_oyaf210-B11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025091815422397600_oyaf210-B12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"2025091815422397600_oyaf210-B13","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.3802\/jgo.2022.33.e67","article-title":"Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma","volume":"33","author":"Tanaka","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"2025091815422397600_oyaf210-B14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025091815422397600_oyaf210-B15","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025091815422397600_oyaf210-B16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025091815422397600_oyaf210-B17","doi-asserted-by":"crossref","first-page":"2171282","DOI":"10.1080\/01443615.2023.2171282","article-title":"Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis","volume":"43","author":"Li","year":"2023","journal-title":"J Obstet Gynaecol"},{"key":"2025091815422397600_oyaf210-B18","doi-asserted-by":"crossref","first-page":"1372077","DOI":"10.3389\/fphar.2024.1372077","article-title":"Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials","volume":"15","author":"Wei","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025091815422397600_oyaf210-B19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","article-title":"Durvalumab with paclitaxel\/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1\/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial","volume":"41","author":"Harter","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025091815422397600_oyaf210-B20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025091815422397600_oyaf210-B21","doi-asserted-by":"crossref","first-page":"116203","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2025091815422397600_oyaf210-B22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025091815422397600_oyaf210-B23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cac2.12157","article-title":"Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN\/VEGFR2 signaling axis in ovarian cancer","volume":"41","author":"Yang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"2025091815422397600_oyaf210-B24","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1126\/scisignal.abc4764","article-title":"The injury response to DNA damage in live tumor cells promotes antitumor immunity","volume":"14","author":"Sriram","year":"2021","journal-title":"Sci Signal"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf210\/63752859\/oyaf210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf210\/63752859\/oyaf210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf210\/63752859\/oyaf210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:42:29Z","timestamp":1758224549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf210\/8200834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf210","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,14]]},"article-number":"oyaf210"}}